Emergent BioSolutions (NYSE:EBS) Upgraded to Buy at StockNews.com

Emergent BioSolutions (NYSE:EBS) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Monday.

A number of other equities analysts have also issued reports on the stock. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Emergent BioSolutions in a research report on Tuesday, January 21st. Benchmark increased their price objective on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th.

Emergent BioSolutions Stock Performance

NYSE EBS traded up $0.20 during trading hours on Monday, hitting $9.70. The company had a trading volume of 695,038 shares, compared to its average volume of 890,394. The business has a 50 day moving average of $9.71 and a 200-day moving average of $9.12. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. Emergent BioSolutions has a 1-year low of $1.48 and a 1-year high of $15.10. The company has a market cap of $525.28 million, a PE ratio of -2.36 and a beta of 1.62.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Jacobs Levy Equity Management Inc. purchased a new stake in Emergent BioSolutions in the 3rd quarter valued at approximately $1,547,000. Oak Hill Advisors LP acquired a new stake in shares of Emergent BioSolutions in the 3rd quarter valued at approximately $9,296,000. Assenagon Asset Management S.A. boosted its stake in shares of Emergent BioSolutions by 74.5% in the third quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock valued at $6,192,000 after buying an additional 316,700 shares in the last quarter. Barclays PLC grew its holdings in Emergent BioSolutions by 361.6% during the third quarter. Barclays PLC now owns 39,308 shares of the biopharmaceutical company’s stock worth $329,000 after acquiring an additional 30,792 shares during the period. Finally, Geode Capital Management LLC raised its position in Emergent BioSolutions by 4.6% in the third quarter. Geode Capital Management LLC now owns 581,958 shares of the biopharmaceutical company’s stock worth $4,861,000 after acquiring an additional 25,776 shares in the last quarter. 78.40% of the stock is currently owned by institutional investors and hedge funds.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.